Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America

被引:46
|
作者
Justo, Nahila [1 ,2 ]
Espinoza, Manuel A. [3 ]
Ratto, Barbara [3 ,4 ]
Nicholson, Martha [2 ]
Rosselli, Diego [5 ]
Ovcinnikova, Olga [6 ]
Marti, Sebastian Garcia [7 ]
Ferraz, Marcos B. [8 ]
Langsam, Martin [9 ]
Drummond, Michael F. [10 ]
机构
[1] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden
[2] ICON Plc, Real World Evidence Strategy & Analyt, Stockholm, Sweden
[3] Pontificia Univ Catolica Chile, Dept Publ Hlth, Santiago, Chile
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Pontificia Univ Javeriana, Clin Epidemiol & Biostat Dept, Bogata, Colombia
[6] ICON Plc, HTA Strategy & Analyt, London, England
[7] Inst Clin Effectiveness & Publ Hlth, Buenos Aires, DF, Argentina
[8] Univ Fed Sao Paulo, Sao Paulo, Brazil
[9] Univ Isalud, Buenos Aires, DF, Argentina
[10] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
关键词
big data; epidemiology; health policy; health technology assessment; Latin America; real-world evidence; TUBERCULOSIS; PREVALENCE; COUNTRIES; COLOMBIA; QUALITY; ACCESS; IMPACT; BRAZIL;
D O I
10.1016/j.jval.2019.01.014
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Real-world evidence (RWE) is increasingly used to inform health technology assessments for resource allocation, which are valuable tools for emerging economies such as in America. Nevertheless, the characteristics and uses in South America are unknown. Objectives: To identify sources, characteristics, and uses of RWE in Argentina, Brazil, Colombia, and Chile, and evaluate the context-specific challenges. The implications for future regulation and responsible management of RWE in the region are also considered. Methods: A systematic literature review, database mapping, and targeted gray literature search were conducted to identify the sources and characteristics of RWE. Findings were validated by key opinion leaders attending workshops in 4 South American countries. Results: A database mapping exercise revealed 407 unique databases. Geographic scope, database type, population, and outcomes captured were reported. Characteristics of national health information systems show efforts to collect interoperable data from service providers, insurers, and government agencies, but that initiatives are hampered by fragmentation, lack of stewardship, and resources. In South America, RWE is mainly used for pharmacovigilance and as pure academic research, but less so for health technology assessment decision making or pricing negotiations and not at all to inform early access schemes. Conclusions: The quality of real-world data in the case study countries vary and RWE is not consistently used in healthcare decision making. Authors recommend that future studies monitor the impact of digitalization and the potential effects of access to RWE on the quality of patient care.
引用
收藏
页码:739 / 749
页数:11
相关论文
共 50 条
  • [1] Real-world evidence: experiences and challenges for decision making in Latin America
    Garcia Marti, Sebastian
    Pichon-Riviere, Andres
    Augustovski, Federico
    Espinoza, Manuel
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [2] The evolution of real-world evidence in healthcare decision making
    Williams, David M.
    Evans, Marc
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023, 22 (06) : 443 - 445
  • [3] REAL WORLD EVIDENCE (RWE) USE IN LATIN AMERICA HEALTHCARE DECISION MAKING: AN STAKEHOLDER SURVEY ANALYSIS
    Costa, L.
    Hincapie, A. L.
    Gilardino, R.
    Tang, B.
    Julian, G.
    Soares, C. S.
    Machnicki, G.
    [J]. VALUE IN HEALTH, 2021, 24 : S194 - S194
  • [4] A Multistakeholder Effort to Further Real-World Evidence in Healthcare Decision Making
    Pizzi, Laura T.
    Willke, Richard J.
    [J]. VALUE IN HEALTH, 2023, 26 (04) : 1 - 2
  • [5] Real-world evidence enhances decision making
    Malone, Daniel C.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12): : 1612 - 1614
  • [6] REAL WORLD DATA AVAILABILITY IN LATIN AMERICA: ASSESSMENT AND IMPLICATIONS FOR RESEARCH AND HEALTHCARE DECISION MAKING
    Monsanto, H.
    Parellada, C.
    Orengo, J.
    Velasco, J. S.
    van Bavel, J.
    Salomonsson, S.
    [J]. VALUE IN HEALTH, 2021, 24 : S157 - S157
  • [7] Making Real-World Evidence More Useful for Decision Making
    Greenfield, Sheldon
    [J]. VALUE IN HEALTH, 2017, 20 (08) : 1023 - 1024
  • [8] Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Hukkelhoven, Mathias
    Rockhold, Frank
    O'Donnell, John
    [J]. CLINICAL THERAPEUTICS, 2022, 44 (03) : 420 - 437
  • [9] Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
    Malone, Daniel C.
    Brown, Mary
    Hurwitz, Jason T.
    Peters, Loretta
    Graff, Jennifer S.
    [J]. VALUE IN HEALTH, 2018, 21 (03) : 326 - 333
  • [10] Real-world evidence for regulatory decision-making: updated guidance from around the world
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Dudinak, Jennifer
    Rockhold, Frank
    Khozin, Sean
    O'Donnell, John
    [J]. FRONTIERS IN MEDICINE, 2023, 10